Stocks · News reference
Cantor Fitzgerald Reiterates Overweight on Omeros, Maintains $22 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Omeros (NASDAQ:OMER) with a Overweight and maintains $22 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Truist Financial, Regions Financial And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures mixed; Truist slips after mixed results, while Telkom Indonesia, Loma Negra, Omeros and others fall premarket.
Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends
Omeros shares are trading lower Friday after the company announced that the EMA’s CHMP upheld its negative opinion on narsoplimab for TA-TMA.
Omeros Receives EMA CHMP Negative Opinion On Its Marketing Authorization Application For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Decision follows re-examination of its original negative opinion adopted in June 2026. An eight-member ad hoc expert group (AHEG) consisting of hematologists, statisticians, and transplant physicians, together with two